Retrospective Study
Copyright ©The Author(s) 2018.
World J Hepatol. Jan 27, 2018; 10(1): 95-104
Published online Jan 27, 2018. doi: 10.4254/wjh.v10.i1.95
Figure 1
Figure 1 Patient flow diagram. In this diagram, treatment response evaluated by contrast-enhanced ultrasonography (CEUS) and/or dynamic computed tomography (CT) immediately, one month and six months after DEB-TACE for hepatocellular carcinoma (HCC) using mRECIST. Findings on CEUS or dynamic CT were evaluated using mRECIST criteria. 1Complete treatment: Disappearance of the tumor enhancement after DEB-TACE by IAUS findings; 2Incomplete treatment: Presence of residual tumor enhancement after DEB-TACE by IAUS findings. CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.